Downloads

1. Here's How FDA's Accelerated Approval Pathway Has Evolved Since '24 5/5/2026

   FDA's accelerated approval guidance kicked off a rebalancing of new drug approval pathways. Since its 2024 release, the agency has been building on it in a few key areas.

2. Development Of An Oncology VHH-ADC Candidate Via Site-Specific Non-Canonical Amino Acid Conjugation 5/5/2026

   Homogeneous ADCs demand precise conjugation chemistry. See how 100% ncAA incorporation and 15 g/L titers were confirmed in a VHH nanobody at bioreactor scale.

3. Why Dilution Gets Tricky: The Role Of Measurement Variability 5/5/2026

   Dilution's effects on downstream processes and final formulation is often understated. A statistical framework can quantify measurement uncertainty's impacts.

4. Pfenex Expression Technology® For ncAA-Enabled Site-Specific Conjugation 5/5/2026

   Non-canonical amino acids enable site-specific modification of therapeutic proteins by introducing a reactive handle at a defined position. Even so, many ncAA programs stall at the development stage. Off-target toxicity, reduced fermentation yields, and the need for reliable incorporation at scale remain key barriers.

5. Gaining An Edge In GLP-1 Production 5/5/2026

   The shortage-driven production of GLP-1 drugs of the past few years is giving way to a long-term operation model characterized by digital enablement and supply chain resilience.

6. A Liquid Chromatography System With A Wide Operating Range 5/4/2026

   Scale purification with confidence using a chromatography platform built for high‑titer, single‑use processes. Wide flow ranges, large columns, and automation‑ready control help reduce changeover time.

7. A Novel Cell Selective Lentiviral Platform For CAR-T Engineering 5/4/2026

   Targeted lentiviral vectors enable rapid CAR‑T cell generation without extensive ex vivo manipulation. See how this approach demonstrates efficient in vitro and in vivo performance.

8. 3 Critical UF/DF Challenges And How To Solve Them 5/4/2026

   High‑concentration mAbs change how UF/DF behaves. Learn how modern TFF platforms help address these challenges and maintain control as formulations move beyond traditional limits.

9. Inside March Biosciences' CD5-Targeting CAR-T Approach 5/4/2026

   Fratricide is one of the key reasons T-cell therapies targeting T-cell malignancies have faltered. March's approach aims to solve that with its MB-105 candidate.

10. Expanding The Capabilities Of Targeted Integration 5/1/2026

    See the demonstration of precise, site‑specific integration of a 50 kb multi‑gene construct into human iPSCs, overcoming size limits of traditional genome‑engineering approaches.